• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Illumina launches new genomic profiling test for cancer in Europe

Illumina launches new genomic profiling test for cancer in Europe

March 15, 2022 By Sean Whooley

Illumina

Illumina (Nasdaq:ILMN) announced today that it launched its TruSight oncology test for assessing multiple tumor genes and biomarkers.

San Diego-based Illumina’s CE-marked TruSight test, which will begin its global launch in Europe, assesses the tumor genes and biomarkers to reveal the specific molecular profile of a patient’s cancer, helping to inform precision medicine decisions.

According to a news release, the new in vitro diagnostic (IVD) complete genome profiling (CGP) kit covers a wide array of current and emerging mutations and biomarkers, maximizing the chances of finding actionable biopsy information for each patient.

Illumina said TruSight assesses biomarkers in 517 cancer-relevant genes in nearly 30 solid tumor types by evaluating both DNA and RNA, along with complex genomic signatures like microsatellite instability (MSI) and tumor mutational burden (TMB). It aims to eliminate the need for separate sequential genetic testing from multiple biopsy procedures, leading to a rapid turnaround time of four to five days for sample-to-clinician reporting, compared to weeks in some cases.

“This innovative and accurate diagnostic kit provides information that clinicians can use to help their patients find available therapies based on clinical guidelines or clinical trials, based on their tumor profile,” Illumina GM of Oncology Kevin Keegan said in the release. “At Illumina, we are proud to bring innovations like this to market and to be at the forefront of unlocking the power of the genome for human benefit.”

Illumina said that its TruSight oncology test is the first IVD kit for PGC with CE mark based on DNA and RNA content.

“Doctors are increasingly matching a patient’s cancer genetics to their therapy,” Illumina CMO Dr. Phil Febbo said. “When a medical center internalizes comprehensive cancer genomic profiling, the multidisciplinary team includes a molecular pathologist who has more control over the biopsy sample and the data generated, and can increase the number of reported cases they can deliver.

“Evidence suggests that when this happens, more patients have access to PGC and precision medicine earlier in their disease process.”

Filed Under: Business/Financial News, Diagnostics, Genomics/Molecular Diagnostics, Oncology Tagged With: Illumina Inc.

More recent news

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Endogenex data supports type 2 diabetes procedure
  • Ambu wins FDA clearance for first single-use cysto-nephroscope

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy